The correlation between ADC and UC clinical activity index (CAI), ESR, respectively, in three groups. Results: ADC value of three groups were (1.55 ± 0.33)×10–3 mm2/s, (2.44 ± 0.34)×10-3 mm2/s, (2.86 ± 0.48) × 10-3 mm2/s, The differences in the three groups were statistically signifeicant

(p < 0.05), and the differences of SNR, SIb/m, Slope among three groups were statistically signifeicant (p < 0.05), also. Mural signal in active group for DWI is highest then inactive group and control group. Conclusion: The correlation among active group, inactive group and control group was inverse with CAI, ESR. Cell density may influence the ADC value of UC mural. DWI is expected to a new safe non-invasive and effective method of evaluating the UC'activity. But the sensitivity and specificity were low when differential diagnosis between the inactive group and control group. Key Word(s): 1. ulcerative colitis; 2. MRI; 3. DWI; Presenting Author: see more P RUTGEERTS Additional Authors: BG FEAGAN, C MARANO, R STRAUSS, J JOHANNS, H ZHANG, C GUZZO, JF COLOMBEL, W REINISCH, P GIBSON, J COLLINS, G JARNEROT, W SANDBORN Corresponding Author: P RUTGEERTS Affiliations: University Hospital Gasthuisberg; Robarts Research Institute; Janssen Research & Development,

LLC.; Janssen Services, LLC.; Hopital Claude Huriez; 5. Universitätsklinik für Innere Medizin IV; Alfred Hospital; Oregon Health Sciences; Orebro University Hospital; University FDA approved Drug Library order of California-San Diego Objective: To evaluate the safety and efficacy of SC GLM maintenance therapy in patients with moderately to severely active (UC) who responded to GLM induction. Methods: 1228 patients were enrolled from the PURSUIT-IV and PURSUIT-SC induction studies. The primary analysis population consisted of patients (n = 464) who responded to GLM induction and were randomized to receive placebo (PBO), GLM 50 mg, or GLM 100 mg at baseline

(wk0) and q4 wks through wk52. Non-randomized patients included 129 who were PBO induction responders who continued on PBO; and 635 who were non-responders to PBO or GLM induction who received GLM 100 mg q4wks. Primary endpoint was clinical response through wk54. Secondary endpoints at both wks 30 and 54 were clinical remission, mucosal healing, and clinical remission among patients in clinical remission at wk0 of this study and clinical remission with corticosteroid discontinuation selleck inhibitor at wk54 among patients receiving corticosteroids at wk0. Safety data is summarized for randomized patients; selected events of interest are summarized for all treated patients. Results: Among the 464 patients in clinical response to GLM who were randomized, 28% discontinued drug prior to the last dosing visit at wk52. Greater proportions of patients receiving GLM 50 mg (47.1%) or GLM 100 mg (50.6%) were in clinical response through wk54 vs PBO (31.4%; p = 0.01 and p < 0.001, resp). Clinical remission for PBO, GLM 100 mg, and GLM 50 mg was 24.1%, 40.4% (p = 0.073), 36.5% (p = 0.